Navigation Links
Amylin Pharmaceuticals to Present at Goldman Sachs 32nd Annual Global Healthcare Conference and Jefferies Global Life Sciences Conference
Date:5/31/2011

SAN DIEGO, May 31, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 12:20 p.m. ET / 9:20 a.m. PT in Palos Verdes, California and at the Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00 a.m. PT in New York.  Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Goldman Sachs conference.  Mark Foletta, senior vice president, finance and chief financial officer of Amylin, will provide a corporate overview at the Jeffries conference.

The presentations will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recordings will be made available on the website following the events. To access the live webcasts, please log on to Amylin's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin to Advance Key Value-Driving Opportunities in 2011
2. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
3. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
6. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
7. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
8. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
(Date:3/22/2017)... 2017   Boston Biomedical , an industry leader ... target cancer stemness pathways, today announced its Board of ... Chief Executive Officer, effective April 24, 2017. ... , M.D., FACP, who has led Boston Biomedical since ... leadership, Boston Biomedical has grown from a "garage startup" ...
(Date:3/22/2017)... ... ... executive recruitment firm, Slone Partners, is proud to have been named a Top 50 ... Scanlon Media is one of the most respected life science publications in the United ... , “It is a great honor for Slone Partners to be part of this ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical ... desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is ... antibodies. , To meet this demand, the team at SCIEX has developed ...
Breaking Biology Technology:
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
Breaking Biology News(10 mins):